J Hepatol

Journal of hepatology · ISSN 0168-8278

41 Publications in this journal
  1. Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.

    Elkrief L et al. · J Hepatol · 2023

    FibroTest Alcohol

  2. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

    Rinella ME et al. · J Hepatol · 2022

    FibroTest Metabolic

  3. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019

    FibroTest Alcohol

  4. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review

    Vilar-Gomez E et al. · J Hepatol · 2018

    FibroTest Metabolic

  5. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016

    FibroTest Metabolic

  6. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016

    FibroTest HCV

  7. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015

    FibroTest Alcohol HBV HCV +3

  8. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.

    Leroy V et al. · J Hepatol · 2014

    FibroTest HBV HCV

  9. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014

    ActiTest FibroTest HBV

  10. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014

    FibroTest HCV

  11. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013

    ActiTest FibroTest HBV

  12. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013

    FibroTest Alcohol HBV HCV +3

  13. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013

    FibroTest HCV

  14. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012

    FibroTest HCV

  15. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012

    FibroTest Alcohol

  16. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012

    ActiTest FibroTest HBV

  17. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012

    FibroTest HCV

  18. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012

    ActiTest FibroTest Alcohol HBV +4

  19. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012

    FibroTest Alcohol HBV HCV +1

  20. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011

    FibroTest Metabolic

  21. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011

    ActiTest FibroTest HCV

  22. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011

    FibroTest HBV HCV HIV

  23. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011

    FibroTest HCV

  24. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011

    ActiTest AshTest FibroTest NashTest +7

  25. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

    Terrier B et al. · J Hepatol · 2011

    ActiTest FibroTest HCV HIV

  26. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010

    FibroTest Other

  27. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.

    Calès P et al. · J Hepatol · 2010

    FibroTest HCV HIV

  28. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010

    FibroTest HBV HCV HIV

  29. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.

    Dai CY et al. · J Hepatol · 2010

    FibroTest HBV HCV

  30. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010

    FibroTest HCV

  31. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

    Castéra L et al. · J Hepatol · 2009

    FibroTest HCV

  32. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009

    FibroTest Alcohol HBV HCV +1

  33. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009

    FibroTest HBV HIV

  34. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.

    Cacoub P et al. · J Hepatol · 2008

    FibroTest HCV HIV

  35. Implementing non-invasive markers for liver fibrosis in clinical practice.

    Sebastiani G et al. · J Hepatol · 2008

    FibroTest HCV

  36. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

    Halfon P et al. · J Hepatol · 2007

    FibroTest HCV

  37. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

    Castera L et al. · J Hepatol · 2007

    FibroTest HCV

  38. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

    Leroy V et al. · J Hepatol · 2007

    FibroTest HCV

  39. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

    Sebastiani G et al. · J Hepatol · 2006

    FibroTest HCV

  40. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006

    AshTest Alcohol

  41. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003

    ActiTest FibroTest HBV